Literature DB >> 9166304

The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study.

M R Spence1, T S Harwell, M C Davies, J L Smith.   

Abstract

OBJECTIVE: To identify the minimum effective single oral dose of metronidazole for trichomoniasis.
METHODS: Women attending an inner-city sexually transmitted disease clinic who had Trichomonas vaginalis vaginitis diagnosed by microscopy were recruited for this randomized, double-blind study. Subjects were given a 0.5-, 1-, 1.5-, or 2-g single oral dose of metronidazole, taken under direct observation. Demographic information, symptoms, and clinical findings were collected from patient interviews, and physical examinations were conducted at the time of enrollment and at the follow-up visit. The primary outcome measure was treatment success at the follow-up visit, established by negative culture and microscopy.
RESULTS: Three (1.8%) of the 167 women enrolled were excluded because of vomiting after taking metronidazole, and 66 (40%) of the 164 remaining subjects did not return for the follow-up visit. No associations were found between the proportion of subjects lost to follow-up and the characteristics of these subjects across assignment groups. The treatment success ratio was highest in subjects who received the 1.5-g dose (23, 85%), followed by the 2-g (16, 84%), 1-g (18, 62%), and the 0.5-g dose (8, 35%).
CONCLUSION: A single 1.5-g dose of metronidazole has efficacy equivalent to a single 2-g dose for the treatment of T vaginalis vaginitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166304     DOI: 10.1016/s0029-7844(97)81437-8

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  14 in total

1.  Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations.

Authors:  T Meri; T S Jokiranta; L Suhonen; S Meri
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.

Authors:  Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

3.  Trichomonas vaginalis and Human Immunodeficiency Virus Coinfection Among Women Under Community Supervision: A Call for Expanded T. vaginalis Screening.

Authors:  Alissa Davis; Anindita Dasgupta; Dawn Goddard-Eckrich; Nabila El-Bassel
Journal:  Sex Transm Dis       Date:  2016-10       Impact factor: 2.830

4.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

5.  In Vitro Study of the Susceptibility of Clinical Isolates of Trichomonas vaginalis to Metronidazole and Secnidazole.

Authors:  Arindam P Ghosh; Cheri Aycock; Jane R Schwebke
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  Epidemiology and treatment of trichomoniasis.

Authors:  Patricia Kissinger
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

7.  Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing.

Authors:  Megan Clare Craig-Kuhn; Charleigh Granade; Christina A Muzny; Barbara Van Der Pol; Rebecca Lillis; Stephanie N Taylor; Norine Schmidt; David H Martin; Patricia Kissinger
Journal:  Sex Transm Dis       Date:  2019-05       Impact factor: 2.830

8.  Does Antiretroviral Therapy Interfere With the Treatment of Trichomonas vaginalis Among HIV+ Women?

Authors:  Patricia Kissinger; Alys Adamski; Rebecca A Clark; Leandro Mena; Judy Levison; David H Martin
Journal:  Sex Transm Dis       Date:  2013-06       Impact factor: 2.830

Review 9.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Trichomoniasis and HIV interactions: a review.

Authors:  Patricia Kissinger; Alys Adamski
Journal:  Sex Transm Infect       Date:  2013-04-20       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.